MGB Biopharma to Present Poster at Upcoming ASM Microbe Meeting in Boston on 20 June 2016

LinkedIn

Glasgow, Scotland, 14th June 2016 – MGB Biopharma, a biopharmaceutical company developing a truly novel class of anti-infectives to address the major global problem of antibiotic resistance, announces today that Dr Miroslav Ravic, CEO of MGB Biopharma, will present at the upcoming ASM Microbe 2016 meeting in Boston on [20 June 2016].

  • Poster title: A Single-Centre, Double-Blind, Placebo-Controlled Study in Healthy Men to Assess the Safety and Tolerability of Single and Repeated Ascending Doses of MGB-BP-3, a New Class of Antibacterial Agent
  • Date: Monday 20 June 2016
  • Time: 12:30 PM – 2:30 PM

Dr Ravic will show that MGB Biopharma’s lead compound MGB-BP-3, which is orally-administered, was well tolerated in healthy volunteers at all dose levels tested in a Phase I clinical trial, with no dose limiting toxicity or serious adverse events noted. These results refer to the recently successful completion of a Phase I clinical trial of an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile associated disease (CDAD).

MGB-based anti-infectives have the potential to deliver significant advantages over current approaches based on broad, bactericidal activity against many multi-drug resistant and susceptible Gram-positive pathogens. Other compounds from the platform have shown the potential to treat infection caused by Gram-negative, viral, fungal and parasitic organisms.

Dr Miroslav Ravic, CEO of MGB Biopharma, said: “At MGB Biopharma we believe our truly novel minor groove binder technology platform, could for the first time in many years, provide novel agents that offer a real breakthrough in combatting this major global public health concern. Our lead candidate, MGB-BP-3, has shown significant antibacterial activity against a range of important Gram-positive pathogens.”

Dr Ravic added: “We are now in the planning stage for a Phase II clinical trial to investigate the safety and efficacy of MGB-BP-3 in patients with CDAD, following our positive pre-IND meeting with the FDA.”

While pursuing its clinical development activities, MGB Biopharma is now evaluating partnering and funding sources for its lead compound MGB-BP-3, which has the potential to offer a clear differentiated treatment option for patients with life threatening infections caused by resistant and susceptible Clostridium difficile strains.

###

For further information, please contact:

 

MGB Biopharma

Miroslav Ravic, Chief Executive Officer

Or

Dr Dawn Firmin, Head of Project Management

enquiries@mgb-biopharma.com

+44 (0) 208 946 0120

Citigate Dewe Rogerson

David Dible, Sylvie Berrebi

david.dible@citigatedr.co.uk

Sylvie.berrebi@citigatedr.co.uk

+44 (0) 20 7282 1052

 

About MGB Biopharma

MGB Biopharma is a clinical stage company developing a truly novel class of anti-infectives. Its lead candidate, MGB-BP-3, is an antibacterial which is active against a broad range of important multi-resistant and susceptible Gram-positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for the treatment of Clostridium difficile associated disease (CDAD). The Phase I study is complete, and MGB Biopharma is now progressing with Phase II activities for this indication. An intravenous formulation targeting the treatment of a range of systemic hospital acquired Gram-positive infections is in late-stage preclinical development, and a topical formulation for the treatment of serious skin infections showed encouraging efficacy data.

MGB Biopharma has acquired rights to the proprietary minor groove binder (MGB) platform, developed at the University of Strathclyde, Glasgow, with exclusive worldwide licensing rights for all anti-infective fields, including Gram-negative bacteria. This platform provides an opportunity to develop various compounds with a completely new mode of action which are distinct from the antimicrobial drugs used in clinical practice today. As a result many MGB-based drugs offer significant advantages over existing anti-infectives, for example, MGB-BP-3, which exhibits high efficacy against many multi-drug susceptible and resistant Gram-positive pathogens. To date, no resistance to MGB compounds has been observed.

The Company intends to work with partners to fully capitalise on the multiple value creating opportunities offered by its broad and innovative anti-infectives platform.

The Company, founded in 2010 and headquartered in Glasgow, Scotland, is backed by Scottish investors including Archangel Investors Limited, Barwell, TRI Cap and the Scottish Investment Bank, Scottish Enterprise.

For more information please visit www.mgb-biopharma.com

Or follow MGB Biopharma on Twitter @MGB_Biopharma

 

 

 

 

 

 

 

LinkedIn